ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.
Saved in:
| Title: | ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. |
|---|---|
| Authors: | Hoang VT; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., Matossian MD; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., Ucar DA; Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, United States., Elliott S; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., La J; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., Wright MK; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., Burks HE; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., Perles A; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States., Hossain F; Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, United States., King CT; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, United States., Browning VE; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, United States., Bursavich J; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, United States., Fang F; Medical Sciences, School of Medicine, Indiana University Bloomington, Bloomington, IN, United States., Del Valle L; Department of Pathology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, United States., Bhatt AB; Department of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States., Cavanaugh JE; Department of Pharmacology, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States., Flaherty PT; Department of Medicinal Chemistry, School of Pharmacy, Duquesne University, Pittsburgh, PA, United States., Anbalagan M; Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, United States., Rowan BG; Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, United States., Bratton MR; Cellular and Molecular Biology Core, Xavier University, New Orleans, LA, United States., Nephew KP; Medical Sciences, School of Medicine, Indiana University Bloomington, Bloomington, IN, United States., Miele L; Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, United States., Collins-Burow BM; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States.; Tulane Cancer Center, New Orleans, LA, United States., Martin EC; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, United States., Burow ME; Section of Hematology & Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States.; Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2020 Aug 03; Vol. 10, pp. 1164. Date of Electronic Publication: 2020 Aug 03 (Print Publication: 2020). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2020.01164 |
